

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Broncus Holding Corporation**  
**壑博医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2216)**

**VOLUNTARY ANNOUNCEMENT**

**BRONCTARGET® TARGETED LUNG DENERVATION RADIOFREQUENCY  
ABLATION SYSTEM ENTERS THE INNOVATIVE MEDICAL DEVICE  
SPECIAL REVIEW PROCEDURE**

This announcement is made by Broncus Holding Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors of the latest updates on the business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company’s BroncTarget® Targeted Lung Denervation Radiofrequency Ablation System (the “**BroncTarget® System**”) has officially entered the Innovative Medical Device Special Review Procedure of the National Medical Products Administration of China (the “**NMPA**”) (disclosed as “Pulmonary Radiofrequency Ablation System” in the NMPA public notice document), marking the recognition by national regulatory authorities of the product’s core technological originality and significant clinical value.

Targeted lung denervation (TLD) is a breakthrough interventional technology for moderate to severe chronic obstructive pulmonary disease (COPD). It precisely delivers radiofrequency energy to neural targets through bronchoscopy, aiming to fundamentally inhibit abnormal airway constriction and excessive mucus secretion, thereby improving symptoms such as cough, expectoration, and dyspnea. This technology, combined with conventional pharmacological therapy in an “intervention + medication” comprehensive management approach, provides a new treatment option particularly for patients whose symptoms remain poorly controlled after conventional drug therapy. The BroncTarget® System innovatively incorporates circular multi-electrode design, adjustable loop diameter, differentiated radiofrequency energy output, real-time temperature and impedance monitoring and adjusting, and intelligent cold saline irrigation, ensuring both efficacy and safety of radiofrequency ablation.

Currently, the confirmatory clinical trial of the BroncTarget® System is progressing in an orderly manner, with 28 hospitals across the country simultaneously advancing patient recruitment.

**Cautionary Statement:** There is no assurance that the BroncTarget® System will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Broncus Holding Corporation**  
**XU Hong**  
*Chairman*

Hong Kong, January 12, 2026

*As at the date of this announcement, the Board comprises Mr. Hong Xu as executive Director, Mr. Ao Zhang and Ms. Yanhong Kuang as non-executive Directors, and Dr. Pok Man Kam, Ms. Yee Sin Wong and Dr. David Scott Lim as independent non-executive Directors.*